Pfizer Inc

NYSE: PFE
$26.72
+$0.53 (+2.0%)
Closing Price on November 13, 2024

PFE Articles

Drug prices have been under pressure due to the campaign rhetoric, and short interest has increased in most of these selected pharmaceutical stocks.
November 9, 2016: Markets opened lower again Wednesday following the unexpected results of Tuesday’s election. Overnight DJIA futures dropped some 800 points at one point, but equities gained...
24/7 Wall St. has identified several immediate winners from a Donald Trump presidency. These are all surging higher.
FactSet set its computers to work counting the number of times company executives mentioned the word "election" during third-quarter conference calls.
November 3, 2016: Markets opened higher Thursday but drifted lower around midday. Friday morning brings the non-farm payroll report which is expected to show that 178,000 jobs were added in October...
The top analyst upgrades, downgrades and initiations seen on Wednesday morning include Brookdale Senior Living, Frontier Communications, Nike, Norfolk Southern, Pfizer, Nucor and Xylem.
November 1, 2016: Markets opened higher again Tuesday but drifted lower beginning in the mid-morning, and appear on track for a lower close. Consumer discretionary and real-estate sectors were among...
As Pfizer is a major player in the pharmaceutical industry, this earnings report is important in setting a direction that other companies can rally behind.
Pfizer is scheduled to release its third-quarter financial results before the markets open on Tuesday.
24/7 Wall St. has put together a preview of Pfizer, Starbucks and some of the major companies reporting their quarterly results this week.
The October 14 short interest data have been compared with the previous figures, and for the selected pharmaceutical stocks short interest was mixed.
Savvy investors know that often the best time to buy a stock, especially a solid company with a mature franchise, is when an event that falls outside the norm affects the stock's price.
Alkermes' positive Phase 3 results for its novel antidepressant is serving as a rising tide — a storm surge even — for many biotech companies in the depression space.
Americans generally would like to spend less money on health care. One way that this can be and will be accomplished is through the continued use and expanded use of generic drugs.
It is very rare for a year to go exactly as analysts and investors might expect. After all, predicting a move a day or a week out is hard enough — and this is also an election year when the Federal...